Spots Global Cancer Trial Database for A Long-Term Study of Rovalpituzumab Tesirine
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Long-Term Study of Rovalpituzumab Tesirine
Official Title: A Multicenter, Long-Term, Rollover Extension Study of Rovalpituzumab Tesirine
Study ID: NCT03543358
Conditions
Study Description
Brief Summary: The purpose of this long-term, extension study is to provide ongoing safety and efficacy follow-up of subjects who participated in a rovalpituzumab tesirine study that has completed the primary analysis and that is closing.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Arizona Oncology Associates, PC-HOPE (Rudasill) /ID# 204818, Tucson, Arizona, United States
City of Hope National Medical Center /ID# 204885, Duarte, California, United States
Univ of Pittsburgh Med Ctr /ID# 204763, Pittsburgh, Pennsylvania, United States
Contact Details
Name: AbbVie Inc.
Affiliation: AbbVie
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
